These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1189 related articles for article (PubMed ID: 31478503)

  • 41. Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs).
    Gao W; Zhang J; Xiang J; Zhang L; Wu C; Dhal PK; Chen B
    Curr Cancer Drug Targets; 2016; 16(6):469-79. PubMed ID: 27174056
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibody drug conjugate: the "biological missile" for targeted cancer therapy.
    Fu Z; Li S; Han S; Shi C; Zhang Y
    Signal Transduct Target Ther; 2022 Mar; 7(1):93. PubMed ID: 35318309
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.
    Chu Y; Zhou X; Wang X
    J Hematol Oncol; 2021 Jun; 14(1):88. PubMed ID: 34090506
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibody-Drug Conjugates Containing Payloads from Marine Origin.
    Cheng-Sánchez I; Moya-Utrera F; Porras-Alcalá C; López-Romero JM; Sarabia F
    Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 36005497
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
    Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass.
    Datta-Mannan A; Choi H; Stokell D; Tang J; Murphy A; Wrobleski A; Feng Y
    AAPS J; 2018 Sep; 20(6):103. PubMed ID: 30255287
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates.
    Frigerio M; Kyle AF
    Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibody-Drug Conjugates-A Tutorial Review.
    Baah S; Laws M; Rahman KM
    Molecules; 2021 May; 26(10):. PubMed ID: 34063364
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Brief Introduction to Antibody-Drug Conjugates for Toxicologic Pathologists.
    Mecklenburg L
    Toxicol Pathol; 2018 Oct; 46(7):746-752. PubMed ID: 30295169
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fate of Antibody-Drug Conjugates in Cancer Cells.
    Chalouni C; Doll S
    J Exp Clin Cancer Res; 2018 Feb; 37(1):20. PubMed ID: 29409507
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibody-drug conjugates- stability and formulation.
    Duerr C; Friess W
    Eur J Pharm Biopharm; 2019 Jun; 139():168-176. PubMed ID: 30940541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibody drug conjugates: Progress, pitfalls, and promises.
    Mukherjee A; Waters AK; Babic I; Nurmemmedov E; Glassy MC; Kesari S; Yenugonda VM
    Hum Antibodies; 2019; 27(1):53-62. PubMed ID: 30223393
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes.
    Drake PM; Albers AE; Baker J; Banas S; Barfield RM; Bhat AS; de Hart GW; Garofalo AW; Holder P; Jones LC; Kudirka R; McFarland J; Zmolek W; Rabuka D
    Bioconjug Chem; 2014 Jul; 25(7):1331-41. PubMed ID: 24924618
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens.
    Menezes B; Cilliers C; Wessler T; Thurber GM; Linderman JJ
    AAPS J; 2020 Jan; 22(2):29. PubMed ID: 31942650
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110.
    Domínguez JM; Pérez-Chacón G; Guillén MJ; Muñoz-Alonso MJ; Somovilla-Crespo B; Cibrián D; Acosta-Iborra B; Adrados M; Muñoz-Calleja C; Cuevas C; Sánchez-Madrid F; Avilés P; Zapata JM
    J Hematol Oncol; 2020 Apr; 13(1):32. PubMed ID: 32264921
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.
    Singh SK; Luisi DL; Pak RH
    Pharm Res; 2015 Nov; 32(11):3541-71. PubMed ID: 25986175
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody drug conjugates.
    Bakhtiar R
    Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.